# ulcerative colitis (UC) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 41167
- Completion tokens: 16028
- Reasoning tokens: 0
- Total tokens: 57195
- API requests reported: 3
- Elapsed seconds: 88.033
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 3/5; original repeat 4; model vendor: DeepSeek

---
# Multidimensional Interpretation of Ulcerative Colitis Transcriptomic Data

## 1. Overall Biological Interpretation

The current transcriptomic comparison of ulcerative colitis (UC) versus healthy control colonic mucosal tissue reveals a coordinated molecular signature dominated by **innate immune activation, epithelial stress responses, and metabolic reprogramming**. The upregulated genes (40/100) converge on antimicrobial defense, neutrophil chemotaxis, and acute-phase inflammatory programs, while the downregulated genes (60/100) are enriched for absorptive/transport functions, xenobiotic metabolism, and differentiated epithelial identity markers.

The most striking pattern is the **reciprocal relationship between inflammatory and homeostatic programs**: genes encoding innate antimicrobial effectors (DUOX2, LCN2, S100A8, S100P, CHI3L1, REG4) and neutrophil chemoattractants (CXCL1, CXCL2, CXCL3) are strongly induced, while genes encoding mature colonocyte functions—water transport (AQP7, AQP8), bile acid transport (SLC51A), xenobiotic metabolism (CYP2B6, UGT2A3, ABCG2), and absorptive solute carriers (SLC16A1, SLC23A1/3)—are markedly suppressed. This pattern is consistent with **loss of differentiated epithelial function and acquisition of a reactive, injury-associated phenotype**, a hallmark of active UC mucosa.

The data also show evidence of **extracellular matrix remodeling** (MMP3, TNC, TGM2, PDPN, FILIP1L), **immune checkpoint/regulatory signaling** (CTLA4, SOCS3, IL1RN, IRAK3), and **reduced ketogenesis/lipid metabolism** (HMGCS2, LIPC, ACSF2), suggesting that the transcriptomic changes extend beyond simple inflammation to encompass broader epithelial and metabolic dysfunction.

---

## 2. Core Biological Programs

### Program 1: Innate Antimicrobial Defense and Reactive Oxygen/Nitrogen Production

- **Direction**: Upregulated
- **Supporting genes**: DUOX2, DUOXA2, LCN2, S100A8, S100P, PI3, CHI3L1, REG4, SERPINB5, SLC6A14
- **Standardized pathway**: KEGG IL-17 signaling pathway; Reactome "Detoxification of Reactive Oxygen Species" (for DUOX2); GO antimicrobial humoral response
- **Rationale**: DUOX2 (log2FC=4.666) and its maturation factor DUOXA2 (log2FC=2.892) encode the epithelial NADPH oxidase system that generates hydrogen peroxide as an antimicrobial defense. LCN2 (log2FC=2.668) sequesters bacterial siderophores, S100A8 (log2FC=3.799) is a calprotectin subunit with antimicrobial and alarmin functions, and PI3 (log2FC=2.208) is a secretory leukocyte protease inhibitor. The coordinated induction of these genes indicates an **active epithelial antimicrobial response**, likely driven by IL-17 and NF-κB signaling in the inflamed mucosa.
- **Evidence strength**: Strong direct statistical support (all genes FDR < 1×10⁻¹⁰); pathway co-membership in IL-17 signaling is plausible but formal enrichment was not computed. Limitation: some of these genes (e.g., S100A8) are also expressed by infiltrating myeloid cells, so the epithelial contribution cannot be resolved from bulk tissue data.

### Program 2: Neutrophil Chemotaxis and Acute Inflammatory Signaling

- **Direction**: Upregulated
- **Supporting genes**: CXCL1 (log2FC=3.456), CXCL2 (log2FC=2.799), CXCL3 (log2FC=2.330), VNN1 (log2FC=3.199), SOCS3 (log2FC=2.786), IRAK3 (log2FC=1.782), IL1RN (log2FC=2.876)
- **Standardized pathway**: KEGG IL-17 signaling pathway; KEGG Chemokine signaling pathway; GO neutrophil chemotaxis
- **Rationale**: The three CXC chemokines (CXCL1/2/3) are canonical CXCR2 ligands that recruit neutrophils to the inflamed mucosa—a defining feature of active UC. SOCS3 and IRAK3 are negative regulators of cytokine signaling (JAK-STAT and TLR/IL-1 pathways, respectively), suggesting concurrent **feedback inhibition of inflammatory signaling**. IL1RN (interleukin-1 receptor antagonist) is an endogenous anti-inflammatory mediator, and VNN1 (pantetheinase) regulates glutathione metabolism and macrophage migration.
- **Evidence strength**: Strong direct statistical support; CXCL1/2/3 share a common receptor (CXCR2) and are co-regulated under IL-17/NF-κB signaling. Limitation: the simultaneous upregulation of pro-inflammatory chemokines and their negative regulators (SOCS3, IRAK3, IL1RN) may reflect a mixed cellular composition (epithelial + immune) rather than a single coherent program.

### Program 3: Loss of Differentiated Epithelial Absorptive/Transport Function

- **Direction**: Downregulated
- **Supporting genes**: AQP8 (log2FC=-4.417), AQP7 (log2FC=-2.322), SLC51A (log2FC=-3.711), SLC16A1 (log2FC=-2.375), SLC23A1 (log2FC=-2.402), SLC23A3 (log2FC=-1.929), SLC19A3 (log2FC=-1.341), ABCG2 (log2FC=-2.919), ABCB11 (log2FC=-1.148)
- **Standardized pathway**: GO fluid transport (GO:0042044), water transport (GO:0006833), carboxylic acid transport (GO:0046942); KEGG Bile secretion
- **Rationale**: The coordinated downregulation of aquaporins (AQP7, AQP8), apical/basolateral solute carriers (SLC51A, SLC16A1, SLC23A1/3), and efflux transporters (ABCG2, ABCB11) indicates **loss of mature colonocyte absorptive capacity**. AQP8 is the major colonic water channel; its near-complete suppression (log2FC=-4.417) is particularly striking and is consistent with impaired water transport in inflamed UC mucosa. SLC51A is an apical sodium-dependent bile acid transporter; its loss, along with ABCB11 (BSEP), suggests disrupted bile acid handling.
- **Evidence strength**: Strong direct statistical support; pathway membership in fluid/water transport is supported by Reactome records for AQP7/AQP8. Limitation: downregulation of these transporters could reflect either transcriptional repression in surviving colonocytes or **loss of differentiated epithelial cells** due to injury—bulk tissue cannot distinguish these mechanisms.

### Program 4: Suppressed Xenobiotic Metabolism and Detoxification

- **Direction**: Downregulated
- **Supporting genes**: CYP2B6 (log2FC=-2.777), CYP2B7P (log2FC=-2.724), UGT2A3 (log2FC=-2.677), GBA3 (log2FC=-3.002), HMGCS2 (log2FC=-3.445), DEFB1 (log2FC=-2.305), MOCS1 (log2FC=-1.572)
- **Standardized pathway**: KEGG drug metabolism—cytochrome P450; GO xenobiotic metabolic process
- **Rationale**: The suppression of cytochrome P450 enzymes (CYP2B6, CYP2B7P), UDP-glucuronosyltransferases (UGT2A3), and the molybdenum cofactor synthesis gene MOCS1 indicates **reduced xenobiotic and drug-metabolizing capacity** in UC mucosa. GBA3 (cytosolic β-glucosidase) and HMGCS2 (mitochondrial ketogenesis enzyme) further suggest broad metabolic suppression. DEFB1 (human β-defensin-1) is constitutively expressed in healthy colon but suppressed in UC, consistent with previous reports of antimicrobial peptide dysregulation.
- **Evidence strength**: Moderate-to-strong direct statistical support; pathway membership is plausible but formal enrichment was not computed. Limitation: some of these genes (e.g., CYP2B6) show probe-level ambiguity in the dataset (CYP2B7P|CYP2B6 chimeric rows), and the biological significance of suppressing xenobiotic metabolism in UC is less well established than the inflammatory programs.

### Program 5: Extracellular Matrix Remodeling and Epithelial-Mesenchymal Transition-like Response

- **Direction**: Upregulated
- **Supporting genes**: MMP3 (log2FC=4.642), TNC (log2FC=2.579), TGM2 (log2FC=1.907), PDPN (log2FC=2.539), PRRX1 (log2FC=2.907), CDH3 (log2FC=2.293), FILIP1L (log2FC=1.864), TRIM29 (log2FC=2.832)
- **Standardized pathway**: GO extracellular matrix organization; KEGG Rheumatoid arthritis (shared MMP/chemokine program); Reactome ECM degradation
- **Rationale**: MMP3 (stromelysin-1) is a major matrix-degrading enzyme strongly induced in UC and correlates with disease severity. TNC (tenascin-C) is an injury-associated ECM glycoprotein, TGM2 (tissue transglutaminase) cross-links ECM proteins and is induced by inflammation, and PDPN (podoplanin) marks reactive stromal/fibroblast populations. PRRX1 is a mesenchymal transcription factor, and TRIM29 is an epithelial marker associated with injury responses. The coordinated induction of these genes suggests **active tissue remodeling and a partial epithelial-to-mesenchymal transition-like response** in the injured mucosa.
- **Evidence strength**: Moderate direct statistical support; STRING records show TGM2 and TNC connect to ITGB1 (integrin β1) within the selected cohort. Limitation: ECM remodeling genes are expressed by multiple cell types (fibroblasts, epithelial, immune), and the direction of causality (inflammation→remodeling vs. remodeling→inflammation) cannot be determined from this dataset.

---

## 3. Key Genes and Interaction Modules

### 1. DUOX2 / DUOXA2 module
- **Direction**: Both upregulated (DUOX2 log2FC=4.666; DUOXA2 log2FC=2.892)
- **Role**: Epithelial antimicrobial H₂O₂ production; core of Program 1
- **Gene-gene relationship**: Direct physical interaction—DUOXA2 is the maturation factor required for DUOX2 trafficking to the plasma membrane and enzymatic activity (well-established biochemistry)
- **Evidence**: Direct dataset (both strongly significant); Reactome records place DUOX2 in ROS detoxification; literature supports DUOX2 induction in IBD mucosa

### 2. CXCL1 / CXCL2 / CXCL3 chemokine module
- **Direction**: All upregulated (log2FC=3.456, 2.799, 2.330)
- **Role**: Neutrophil recruitment via CXCR2; core of Program 2
- **Gene-gene relationship**: Pathway co-membership (all three are CXCR2 ligands and co-regulated by IL-17/NF-κB); STRING records show CXCR2 as a common interaction partner. This is **not** direct physical interaction between the chemokines themselves.
- **Evidence**: Direct dataset; STRING network evidence; literature supports CXCL chemokine elevation in UC

### 3. AQP8 / AQP7 water transport module
- **Direction**: Both downregulated (AQP8 log2FC=-4.417; AQP7 log2FC=-2.322)
- **Role**: Loss of colonic water transport; key feature of Program 3
- **Gene-gene relationship**: Pathway co-membership (both are aquaporin family members in Reactome "Passive transport by Aquaporins"); STRING records show shared interaction partners (AQP11, AQP12A). No direct physical interaction is established between AQP7 and AQP8.
- **Evidence**: Direct dataset; Reactome and MyGene pathway records; literature supports AQP8 loss in UC

### 4. SLC6A14
- **Direction**: Upregulated (log2FC=4.849; the strongest effect in the dataset)
- **Role**: Amino acid transporter; may support epithelial repair or serve as a marker of inflamed epithelium
- **Gene-gene relationship**: No clear interaction module in the current cohort; functional relationship to other SLC transporters is putative
- **Evidence**: Direct dataset (extremely significant); literature associates SLC6A14 with IBD susceptibility loci. However, its specific role in UC pathogenesis remains incompletely defined.

### 5. MMP3 / TNC / TGM2 ECM module
- **Direction**: All upregulated (MMP3 log2FC=4.642; TNC log2FC=2.579; TGM2 log2FC=1.907)
- **Role**: Matrix degradation and remodeling; core of Program 5
- **Gene-gene relationship**: STRING records show TGM2 and TNC both connect to ITGB1 (integrin β1), suggesting pathway co-membership in ECM-integrin signaling. MMP3 and TNC may interact functionally (MMP3 can cleave TNC), but direct physical interaction is not established in the retrieved records.
- **Evidence**: Direct dataset; STRING network evidence; literature supports MMP3 and TNC elevation in UC

### 6. S100A8 / S100P / LCN2 antimicrobial module
- **Direction**: All upregulated (S100A8 log2FC=3.799; S100P log2FC=1.775; LCN2 log2FC=2.668)
- **Role**: Alarmins and antimicrobial peptides; core of Program 1
- **Gene-gene relationship**: STRING records show S100A8 connects to CDH1 (E-cadherin); LCN2 and S100A8 are both induced by IL-17/NF-κB but no direct physical interaction is established. Co-expression is likely given shared transcriptional regulation.
- **Evidence**: Direct dataset; STRING network evidence; literature strongly supports S100A8 (calprotectin) as a UC biomarker

### 7. CTLA4 / SOCS3 / IL1RN immune regulatory module
- **Direction**: All upregulated (CTLA4 log2FC=2.616; SOCS3 log2FC=2.786; IL1RN log2FC=2.876)
- **Role**: Negative feedback of immune activation; counter-regulatory arm of Program 2
- **Gene-gene relationship**: Pathway co-membership in immune regulation; no direct physical interaction among these three. SOCS3 regulates JAK-STAT signaling downstream of IL-6/IL-10; IL1RN blocks IL-1 receptor; CTLA4 is an immune checkpoint. Their co-upregulation likely reflects concurrent activation of both pro- and anti-inflammatory programs.
- **Evidence**: Direct dataset; literature supports all three in IBD immune regulation

### 8. ABCG2 / ABCB11 / SLC51A bile acid and efflux module
- **Direction**: All downregulated (ABCG2 log2FC=-2.919; ABCB11 log2FC=-1.148; SLC51A log2FC=-3.711)
- **Role**: Loss of bile acid and xenobiotic transport; component of Programs 3 and 4
- **Gene-gene relationship**: Pathway co-membership (KEGG Bile secretion); no direct physical interaction established
- **Evidence**: Direct dataset; KEGG pathway records; literature supports bile acid dysregulation in IBD

### 9. CHI3L1 / REG4 / PI3 secretory protein module
- **Direction**: All upregulated (CHI3L1 log2FC=4.590; REG4 log2FC=2.051; PI3 log2FC=2.208)
- **Role**: Secreted glycoproteins with antimicrobial and tissue-repair functions
- **Gene-gene relationship**: Co-expression under inflammatory stimuli is plausible; no direct physical interaction or shared pathway membership is established in the retrieved records
- **Evidence**: Direct dataset; literature supports CHI3L1 (YKL-40) elevation in IBD

### 10. HMGCS2 / G6PC / TAT metabolic module
- **Direction**: All downregulated (HMGCS2 log2FC=-3.445; G6PC log2FC=-1.523; TAT log2FC=-1.189)
- **Role**: Suppressed ketogenesis, gluconeogenesis, and amino acid metabolism—indicative of metabolic reprogramming in inflamed colonocytes
- **Gene-gene relationship**: Pathway co-membership in metabolic processes; no direct physical interaction
- **Evidence**: Direct dataset; literature supports HMGCS2 loss in UC and colorectal cancer

---

## 4. Validation Priorities

### Priority 1: Epithelial antimicrobial response (DUOX2/DUOXA2/LCN2)
- **Classification**: Mechanistic hypothesis
- **Why prioritize**: DUOX2 is the strongest upregulated gene (log2FC=4.666) and represents a plausible epithelial-intrinsic driver of UC pathology
- **Dataset evidence**: Strong statistical support; DUOX2/DUOXA2 co-upregulation is internally consistent
- **External evidence**: Literature supports DUOX2 induction in IBD and its role in H₂O₂-mediated antimicrobial defense; however, whether DUOX2 activity is protective or tissue-damaging in UC remains debated
- **Next step**: Single-cell RNA-seq or immunohistochemistry to localize DUOX2 expression to epithelium; functional assays (knockdown/overexpression in colon organoids) to test H₂O₂ production and effects on epithelial survival
- **Current status**: **Supported hypothesis** (not established causality)

### Priority 2: Loss of AQP8 and water transport as a functional epithelial marker
- **Classification**: Biomarker
- **Why prioritize**: AQP8 is the most strongly downregulated gene (log2FC=-4.417) and is a colonocyte-specific water channel with clear functional relevance
- **Dataset evidence**: Strong statistical support; AQP7 co-downregulation strengthens the pattern
- **External evidence**: Literature reports AQP8 loss in UC and colon cancer; Reactome confirms aquaporin passive transport pathway
- **Next step**: Validate AQP8 protein loss by immunohistochemistry in an independent UC cohort; test whether AQP8 expression correlates with disease activity scores or response to therapy
- **Current status**: **Supported hypothesis** for AQP8 as a disease-state biomarker; external statistical validation was not performed

### Priority 3: CXCL1/2/3–CXCR2 axis as a therapeutic target
- **Classification**: Therapeutic target
- **Why prioritize**: Neutrophil infiltration is a hallmark of active UC, and CXCR2 blockade is an active area of drug development
- **Dataset evidence**: Three independent chemokine ligands are all strongly upregulated
- **External evidence**: CXCR2 antagonists exist in clinical development for inflammatory diseases; however, drug existence does not constitute evidence of efficacy in UC
- **Next step**: Preclinical testing of CXCR2 antagonists in mouse colitis models; confirm CXCR2 expression on infiltrating neutrophils in UC tissue
- **Current status**: **Exploratory hypothesis** (no direct therapeutic efficacy data in this dataset)

### Priority 4: Distinguishing epithelial loss versus transcriptional repression of transporters
- **Classification**: Confounding or composition check
- **Why prioritize**: The coordinated downregulation of AQP8, SLC51A, ABCG2, and CYP enzymes could reflect either genuine transcriptional repression or **loss of differentiated colonocytes** due to mucosal injury and replacement by immature/regenerative cells
- **Dataset evidence**: The pattern is consistent but cannot distinguish mechanisms in bulk tissue
- **External evidence**: Single-cell studies of UC have shown that inflamed mucosa contains a higher fraction of immature/cycling epithelial cells; this could explain the apparent "loss" of differentiation markers
- **Next step**: Single-cell RNA-seq or spatial transcriptomics to determine whether transporter downregulation occurs within surviving differentiated colonocytes or reflects cell-type composition shifts; also quantify epithelial cell fraction (e.g., by EPCAM, KRT20) in the same samples
- **Current status**: **Exploratory hypothesis**; requires dedicated cell-composition analysis

### Priority 5: IL1RN/SOCS3/CTLA4 counter-regulatory axis
- **Classification**: Interaction / network hypothesis
- **Why prioritize**: The co-upregulation of pro-inflammatory (CXCL1/2/3) and anti-inflammatory (IL1RN, SOCS3, CTLA4) genes suggests a dynamic balance that may determine disease course
- **Dataset evidence**: All five genes are strongly upregulated in the current dataset
- **External evidence**: IL-1 receptor antagonist (anakinra) and CTLA4-Ig (abatacept) have been tested in inflammatory diseases; SOCS3 is a well-established JAK-STAT negative regulator. Their combined role in UC mucosal regulation is not fully defined.
- **Next step**: Co-expression network analysis to test whether these genes form a correlated module; functional studies to determine whether IL1RN/SOCS3 induction is protective or merely a marker of inflammation intensity
- **Current status**: **Exploratory hypothesis**; the regulatory relationships are supported by literature but the network hypothesis requires formal testing

---

## 5. Evidence Grounding

### Direct evidence from the input dataset
All 100 selected genes have FDR ≤ 0.01, with 100/100 at FDR ≤ 0.05. The strongest effects are SLC6A14 (up, log2FC=4.849), DUOX2 (up, 4.666), MMP3 (up, 4.642), CHI3L1 (up, 4.590), AQP8 (down, -4.417), and HMGCS2 (down, -3.445). These values are the authoritative statistical basis for all program-level conclusions.

### Pathway / ontology evidence
Reactome records support aquaporin-mediated water transport (AQP7, AQP8), ROS detoxification (DUOX2), and retinoic acid biosynthesis (SDR16C5). KEGG records support bile secretion (ABCB11, ABCG2, SLC51A), IL-17 signaling (CXCL1/2/3, S100A8, LCN2), and PPAR signaling (AQP7). GO records support fluid/water/carboxylic acid transport. **Important caveat**: these are retrieved pathway annotations, not formal enrichment statistics computed from the current dataset.

### Protein interaction / regulatory evidence
STRING records show CXCR2 as a hub connecting CXCL1/2/3, and ITGB1 connecting TGM2/TNC/FREM2. TRRUST records identify transcription factor targets for 31/100 selected genes (not individually enumerated here). These are contextual network annotations, not direct physical interaction evidence unless explicitly stated.

### Disease-association evidence
Literature records support UC associations for BRINP3 (downregulated; PMID 25171508), IRAK3 (upregulated; PMID 40918148), and treatment-response genes (PMID 38059894). GWAS records cover 100/100 selected genes, but the specific UC-associated loci among them are not individually enumerated in the retrieved evidence.

### Expression / tissue-specific evidence
GTEx records cover 91/100 selected genes; HPA covers 85/100. These support colon-specific expression patterns for some genes (e.g., AQP8 is colon-enriched) but do not constitute independent cohort replication.

### Genetic / clinical evidence
ClinVar covers 90/100 genes; OpenTargets covers 92/100. ABCB11 deficiency is documented in neonatal cholestasis (PMID 32808743), and NAT8B is linked to neurodevelopmental phenotypes (PMID 40993340)—both are outside the UC context and illustrate that genetic records must be interpreted disease-specifically.

### Drug / therapeutic evidence
51/100 genes have ClinicalTrials.gov records; 40/100 have ChEMBL records. However, **drug-target existence does not imply therapeutic efficacy in UC**. This evidence class is contextual only.

### Independence assessment
The pathway, interaction, tissue, and literature records are **not independent replication** of the current findings. They may share underlying publications, annotation models, or prediction algorithms. **External statistical validation was not performed**—no independent cohort statistic was supplied.

---

## 6. Limitations and Alternative Explanations

### 1. Cell-composition differences
Bulk mucosal tissue contains epithelium, lamina propria immune cells, fibroblasts, and endothelium. The upregulation of S100A8, CXCL1/2/3, and CTLA4 could reflect increased myeloid/lymphoid infiltration rather than epithelial transcriptional changes. Conversely, the downregulation of AQP8, SLC51A, and CYP enzymes could reflect loss of differentiated epithelial cells. **Investigation**: single-cell RNA-seq or immunohistochemistry to localize key transcripts; deconvolution algorithms (e.g., CIBERSORTx) applied to the bulk data.

### 2. Disease severity and treatment exposure
UC is a heterogeneous disease with variable extent and activity. The current dataset does not specify disease severity, disease extent (proctitis vs. pancolitis), or treatment status (5-ASA, corticosteroids, biologics, immunosuppressants). Treatment can profoundly alter mucosal gene expression—for example, corticosteroids induce IL1RN and SOCS3, which could confound the "counter-regulatory" interpretation. **Investigation**: stratify by treatment and disease activity; collect treatment-naïve samples for validation.

### 3. Probe-level ambiguity and duplicate rows
The ledger notes 43 duplicated genes/probes and several chimeric rows (e.g., CYP2B7P|CYP2B6, NAT8B|NAT8, C1QTNF3|AMACR). These may reflect cross-hybridizing probes or genuine multi-gene transcripts. The CYP2B6/CYP2B7P results, in particular, should be interpreted with caution. **Investigation**: orthogonal validation by qPCR or RNA-seq with unambiguous mapping.

### 4. Association-versus-causation ambiguity
All findings are associative. The upregulation of DUOX2/DUOXA2 could be a protective host response, a driver of tissue damage, or an epiphenomenon. The downregulation of transporters could be a cause of UC-related diarrhea or a consequence of epithelial injury. **Investigation**: functional perturbation studies (organoids, mouse models) to establish direction of causality.

### 5. Broad or nonspecific pathway enrichment
Many of the identified programs (innate immunity, ECM remodeling, metabolic suppression) are shared across inflammatory bowel disease, infection, and even cancer. The current data do not distinguish UC-specific mechanisms from generic mucosal injury responses. **Investigation**: compare with Crohn's disease, infectious colitis, and non-IBD inflammation cohorts to identify UC-specific signatures.

---

## Summary Statement

The transcriptomic data reveal a coherent UC signature of upregulated innate antimicrobial and neutrophil chemotactic programs (DUOX2/DUOXA2, S100A8, LCN2, CXCL1/2/3, MMP3) alongside downregulated differentiated colonocyte functions (AQP8, SLC51A, ABCG2, CYP2B6, HMGCS2), consistent with active mucosal inflammation and epithelial dysfunction; these interpretations are strongly supported by the direct statistical results but require single-cell localization, independent-cohort replication, and functional perturbation studies to establish causality and cell-type specificity.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=62, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
